{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:57:48Z","timestamp":1787313468403,"version":"build-2736575974"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.3593","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T11:30:58Z","timestamp":1587727858000},"page":"e203593","source":"Crossref","is-referenced-by-count":53,"title":["Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function"],"prefix":"10.1001","volume":"3","author":[{"given":"Phuong","family":"Pham","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Lesko","sequence":"additional","affiliation":[{"name":"Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville"},{"name":"Center for Drug Evaluation & Safety, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"issue":"9921","key":"zoi200167r1","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"zoi200167r2","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7326\/0003-4819-157-10-201211200-00532","article-title":"Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.","volume":"157","author":"Adam","year":"2012","journal-title":"Ann Intern Med"},{"issue":"11","key":"zoi200167r3","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1177\/1060028013504741","article-title":"Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?","volume":"47","author":"Hellwig","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"12","key":"zoi200167r4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi200167r5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi200167r6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi200167r7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/hrt.2006.099903","article-title":"Rate control in the medical management of atrial fibrillation.","volume":"93","author":"Camm","year":"2007","journal-title":"Heart"},{"issue":"1","key":"zoi200167r8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"zoi200167r9","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non\u2013vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation.","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"issue":"8","key":"zoi200167r10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jama.2017.20842","article-title":"Drug interactions with non\u2013vitamin K oral anticoagulants.","volume":"319","author":"Vazquez","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"zoi200167r11","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2017.20830","article-title":"Drug interactions with non\u2013vitamin K oral anticoagulants.","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"zoi200167r12","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1001\/jama.2017.20834","article-title":"Drug interactions with non\u2013vitamin K oral anticoagulants.","volume":"319","author":"Linnebur","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"zoi200167r13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jama.2017.20846","article-title":"Drug interactions with non\u2013vitamin K oral anticoagulants.","volume":"319","author":"Sennesael","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"zoi200167r14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jama.2017.20850","article-title":"Drug interactions with non\u2013vitamin K oral anticoagulants.","volume":"319","author":"Wang","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"zoi200167r15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"zoi200167r16","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvz053","article-title":"Breaking the rules for studies using real-world observational data: The case of direct-acting anticoagulants and antiepileptic drugs.","author":"Brown","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"zoi200167r17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/jch.2017.19.issue-2","article-title":"Blood pressure in patients with atrial fibrillation: part 2-treatment.","volume":"19","author":"Cohen","year":"2017","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"zoi200167r18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.2174\/1381612820666141024151119","article-title":"Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches.","volume":"21","author":"Zisaki","year":"2015","journal-title":"Curr Pharm Des"},{"issue":"22","key":"zoi200167r22","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"issue":"5","key":"zoi200167r23","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"3","key":"zoi200167r24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"11","key":"zoi200167r25","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1001\/jamainternmed.2016.5954","article-title":"Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation.","volume":"176","author":"Graham","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"6","key":"zoi200167r26","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use.","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"zoi200167r27","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/pds.4295","article-title":"Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies; V1.0.","volume":"26","author":"Wang","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"zoi200167r28","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/bcp.2013.75.issue-4","article-title":"Oral bioavailability of dabigatran etexilate (Pradaxa) after co-medication with verapamil in healthy subjects.","volume":"75","author":"H\u00e4rtter","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"25","key":"zoi200167r29","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","article-title":"The P-glycoprotein transport system and cardiovascular drugs.","volume":"61","author":"Wessler","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"zoi200167r30","first-page":"6","article-title":"Concomitant use of P-glycoprotein inhibitors with dabigatran or warfarin in the RE-LY trial","volume":"32","author":"Reilly","year":"2011","journal-title":"Eur Heart J"},{"issue":"27","key":"zoi200167r31","first-page":"2137","article-title":"Updated European Heart Rhythm Association practical guide on the use of non\u2013vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary.","volume":"38","author":"Heidbuchel","year":"2017","journal-title":"Eur Heart J"},{"key":"zoi200167r32","doi-asserted-by":"publisher","first-page":"j5058","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ"},{"issue":"9","key":"zoi200167r33","first-page":"958","article-title":"Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention for newly diagnosed and treatment-naive atrial fibrillation patients: an update using 2013-2014 data.","volume":"23","author":"Brown","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"zoi200167r34","first-page":"1319","article-title":"Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-na\u00efve nonvalvular atrial fibrillation.","volume":"22","author":"Brown","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"zoi200167r35","first-page":"741","article-title":"Low-cost generic program use by Medicare beneficiaries: implications for medication exposure misclassification in administrative claims data.","volume":"22","author":"Pauly","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"zoi200167r36","first-page":"1162","article-title":"Prevalence of low-cost generic program use in a nationally representative cohort of privately insured adults.","volume":"21","author":"Pauly","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"zoi200167r37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.sapharm.2016.01.006","article-title":"Utilization of free medication samples in the United States in a nationally representative sample: 2009-2013.","volume":"13","author":"Brown","year":"2017","journal-title":"Res Social Adm Pharm"},{"issue":"6","key":"zoi200167r38","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"zoi200167r19","unstructured":"Pradaxa. Package insert. Boehringer Ingelheim; 2012. Accessed October 7, 2018. https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Pradaxa\/Pradaxa.pdf"},{"key":"zoi200167r20","unstructured":"Xarelto. Package insert. Janssen; 2011. Accessed October 7, 2018. http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/XARELTO-pi.pdf"},{"key":"zoi200167r21","unstructured":"Eliquis. Package insert. Bristol-Myers Squibb; 2012. Accessed October 7, 2018. https:\/\/www.bms.com\/assets\/bms\/ca\/documents\/productmonograph\/ELIQUIS_EN_PM.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2764843\/pham_2020_oi_200167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T11:31:04Z","timestamp":1587727864000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2764843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.3593","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]}}}